{"id":"NCT01125774","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)","officialTitle":"A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients With Episodic Migraine","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-06-01","primaryCompletion":"2011-04-08","completion":"2011-04-08","firstPosted":"2010-05-18","resultsPosted":"2014-10-03","lastUpdate":"2018-10-23"},"enrollment":4548,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Telcagepant","otherNames":["MK-0974"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Telcagepant","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period. This study will also evaluate the safety and tolerability of telcagepant for female migraine participants.","primaryOutcome":{"measure":"Number of Participants With Clinical Adverse Events (AEs)","timeFrame":"Up to 14 days after the last dose of study drug (Up to 6.5 months)","effectByArm":[{"arm":"Telcagepant 140 mg","deltaMin":1582,"sd":0.19},{"arm":"Placebo","deltaMin":804,"sd":0.26}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25926620"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":2660},"commonTop":["Nausea","Dizziness","Nasopharyngitis","Diarrhoea","Dry mouth"]}}